Stay updated with breaking news from Dystrophy Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - ...
BOSTON, January 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT.
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), a clinical-stage pharmaceutical company, Thursday, announced that its investigational drug DYNE-101 has been granted orphan drug
Living organisms have a knack for persisting in the face of challenges. For instance, when genes malfunction, organisms may be able to compensate by activating redundant genes with similar functions, called paralogs.